Personalized Cancer Vaccines

The Federal Republic of Brandenburg, Germany, with its ProFIT Brandenburg Program and the European Union via its European Regional Development Fund (ERDF) supports with 1 Million USD the development of peptides & elephants' exclusive high parallel Ultrasound Peptide Synthesis, USPS®. This state-of-the-art technology will be used to develop personalized vaccines in the treatment of cancer.

Within 2021, peptides & elephants will complete production of the prototype USPS® synthesizer, in accordance with all GMP regulations. The synthesizer will be able to produce hundreds of peptides within a few hours. USPS® will allow a wide application in personalized cancer therapeutics as for the first time it will be possible to get enough affordable personalized peptide cancer vaccines to treat an unlimited number of patients.